Beyond Innovation, Towards Cure
AAVATAR Therapeutics is pioneering gene therapy innovations, forging new paths in treating rare and intractable diseases.
Beyond Innovation, Towards Cure
AAVATAR Therapeutics is pioneering gene therapy innovations, forging new paths in treating rare and intractable diseases.
AAVATAR Therapeutics is dedicated to enhancing human health
and quality of life through cutting-edge biotechnology.
We integrate patient-centric methodologies with advanced science
to develop novel treatments for challenging diseases, delivering them to patients globally.
AAVATAR Therapeutics is dedicated to enhancing human health and quality of life through cutting-edge biotechnology.
We integrate patient-centric methodologies with advanced science to develop novel treatments for challenging diseases, delivering them to patients globally.
PLATFORM
At AAVATAR Therapeutics, clients outline the specific objectives and characteristics of their desired gene therapy,
and we design and produce tailored AAV vectors to meet those needs.
In essence, our platform enables clients to specify treatment goals and target diseases,
allowing us to utilize AI-driven technology to design and produce optimized AAV capsids and genetic constructs.
PIPELINE
AAVATAR Therapeutics' pipeline includes treatments for lysosomal storage diseases (LSDs) and hereditary hearing loss.
We are also advancing preclinical programs targeting central nervous system disorders
and developing gene therapy products for ocular diseases utilizing our AAV platform technology.
PROJECT
AAVATAR Therapeutics has garnered strategic investments
and support from prominent government and industry bodies,
such as the Korea Health Industry Development Institute, the Ministry of SMEs and Startups,
and the Seoul Metropolitan Government, acknowledging our innovative advancements in gene therapy development.
PLATFORM
At AAVATAR Therapeutics, clients outline the specific objectives and characteristics of their desired gene therapy, and we design and produce tailored AAV vectors to meet those needs.
In essence, our platform enables clients to specify treatment goals and target diseases, allowing us to utilize AI-driven technology to design and produce optimized AAV capsids and genetic constructs.
PIPELINE
AAVATAR Therapeutics' pipeline includes treatments for lysosomal storage diseases (LSDs) and hereditary hearing loss.
We are also advancing preclinical programs targeting central nervous system disorders and developing gene therapy products for ocular diseases utilizing our AAV platform technology
PROJECT
AAVATAR Therapeutics has garnered strategic investments and support from prominent government and industry bodies, such as the Korea Health Industry Development Institute, the Ministry of SMEs and Startups, and the Seoul Metropolitan Government, acknowledging our innovative advancements in gene therapy development.
INVESTOR
Numerous leading investors have recognized
AAVATAR Therapeutics' growth potential
and have joined us as financial partners
MEDIA
Founded in September 2020, Aavatar Therapeutics focuses on designing and building a production platform for AAV gene therapy, and has pipelines for lysosomal storage disease (LSD) and hereditary hearing loss.
2024.11.24
[Hit News] Global Eyes on ‘AAV Gene Therapy’… Domestic Development Active as WellFounded in September 2020, Aavatar Therapeutics focuses on designing and building a production platform for AAV gene therapy, and has pipelines for lysosomal storage disease (LSD) and hereditary hearing loss.
2024.11.24
The Ministry of SMEs and Startups (Minister Oh Young-joo) announced on the 27th that it had selected 50 “baby unicorn” companies and 15 potential unicorn companies that have a high potential to grow into unicorn companies.
2024.06.28
[Smart Today] 50 Baby Unicorn Companies and 15 Potential Unicorn Companies Selected for 2024The Ministry of SMEs and Startups (Minister Oh Young-joo) announced on the 27th that it had selected 50 “baby unicorn” companies and 15 potential unicorn companies that have a high potential to grow into unicorn companies.
2024.06.28
Aavatar Therapeutics (CEO Seunghee Cho)’ is expanding its business by receiving 5 billion won in Series A investment from TS Investment, Shinhan Capital, Smilegate Investment, and Wonik Investment Partners in November of last year..
2024.01.17
[The Stock] Gene therapy emerging as a ‘dream drug’… Bio startups compete fiercely for developmentAavatar Therapeutics (CEO Seunghee Cho)’ is expanding its business by receiving 5 billion won in Series A investment from TS Investment, Shinhan Capital, Smilegate Investment, and Wonik Investment Partners in November of last year..
2024.01.17
“We will contribute to patient health and health insurance by solving the root cause of diseases with drugs that work at the genetic level and quickly and economically providing customized drugs through precision medicine,” said CEO Cho.
2023.11.23
[JoongAng Ilbo] Seunghee Cho, CEO of Aavatar Therapeutics, "Leading Gene Therapy with Engineering AVV Development"“We will contribute to patient health and health insurance by solving the root cause of diseases with drugs that work at the genetic level and quickly and economically providing customized drugs through precision medicine,” said CEO Cho.
2023.11.23
Aavatar Therapeutics, a CMO for gene therapy based on a recombinant AAV platform, has completed Series A funding. It is expanding partnerships while securing AAV platform technology in just three years since its establishment.
2023.11.07
[The Bell] Gene Therapy CMO 'Aavatar Therapeutics' Series A ProcurementAavatar Therapeutics, a CMO for gene therapy based on a recombinant AAV platform, has completed Series A funding. It is expanding partnerships while securing AAV platform technology in just three years since its establishment.
2023.11.07
Aavatar Therapeutics announced on the 7th that it had attracted 5 billion won in Series A investment. This investment, led by TS Investment, was participated by Shinhan Capital, Smilegate Investment, and Wonik Investment Partners.
2023.11.07
[Korea Economic Daily] Aavatar Therapeutics Attracts 5 Billion Won Series A InvestmentAavatar Therapeutics announced on the 7th that it had attracted 5 billion won in Series A investment. This investment, led by TS Investment, was participated by Shinhan Capital, Smilegate Investment, and Wonik Investment Partners.
2023.11.07
CEO Cho emphasized, “AAV-based gene therapy is a promising alternative for treating rare diseases,” and “Only a few domestic bio ventures, such as Aavatar Therapeutics, possess AAV platform technology, and they are rare even worldwide.”
2023.03.23
[Edaily] Seunghee Cho, CEO of Aavatar Therapeutics, “All-out effort to secure technology to produce ‘recombinant AAV’, a gene delivery vehicleCEO Cho emphasized, “AAV-based gene therapy is a promising alternative for treating rare diseases,” and “Only a few domestic bio ventures, such as Aavatar Therapeutics, possess AAV platform technology, and they are rare even worldwide.”
2023.03.23
CEO Cho Seung-hee says rare diseases can be cured by improving genetic defects using gene editing and amplification technology. About 80% of the 7,000 rare diseases are caused by genetic sequence mutations.
2022.05.19
[Dong-A Ilbo] Innovation Startup in Hongneung | Aavatar Therapeutics “Cure Rare Incurable Pediatric Diseases with Genes”CEO Cho Seung-hee says rare diseases can be cured by improving genetic defects using gene editing and amplification technology. About 80% of the 7,000 rare diseases are caused by genetic sequence mutations.
2022.05.19
Innovation in gene therapy, changing the lives of patients with rare and incurable diseases.
We are with you through the entire process of rare disease treatment, from the development of AAV platform technology to the production of customized treatments.
COMPANY | AAVATAR Therapeutics
CEO | Seunghee Cho
BUSINESS NUMBER | 235-81-02296
HQ
Unit 1023, Building B, 540 Misa-daero,
Hanam-si, Gyeonggi-do, Republic of Korea
BioHub
Room 203, R&D Center, Seoul Bio Hub, 117-3,
Hoegi-ro, Dongdaemun-gu, Seoul, Republic of Korea
Copyright ⓒ 2025 AAVATAR Therapeutics All rights reserved.
Innovation in gene therapy, changing the lives of patients with rare and incurable diseases.
We are with you through the entire process of rare disease treatment, from the development of AAV platform technology to the production of customized treatments.
MON — FRI (8 AM ~ 5 PM)
TEL | 070-4229-0321
EMAIL | information@aavatartps.com
Customer Center
070-4229-0321
MON~FRI 8:00 ~ 17:00
COMPANY | AAVATAR Therapeutics CEO | Seunghee Cho BUSINESS NUMBER | 235-81-02296
HQ | Unit 1023, Building B, 540 Misa-daero, Hanam-si, Gyeonggi-do, Republic of Korea
BioHub | Room 203, R&D Center, Seoul Bio Hub, 117-3, Hoegi-ro, Dongdaemun-gu, Seoul, Republic of Korea
Copyright ⓒ 2025 AAVATAR Therapeutics All rights reserved. | SITE BY. DOTCLE
